The Company also completed its previously announced lease termination and buyout transaction under which we received $4.1 million and successfully relocated its corporate headquarters to a more cost effective and better equipped facility."
Mr. Wilds concluded, "We are very encouraged by our achievement of important business and clinical milestones during the past quarter. By continuing to focus on partnering our lead product candidates, limiting additional drug development initiatives to those already partnered and in active collaborations, we expect that the net proceeds from the lease buyout and our current financial resources together with continuing expense management should be sufficient to fund our operations through 2009."
Total revenues, which consist of royalty revenue from our collaboration agreements, increased 14%, or $28,834 to $236,308 for the three months ended September 30, 2008, compared to $207,474 for the same period in 2007. This increase is primarily due to higher royalty income from our relationship with Perrigo.
Total revenues decreased 55% or $968,013 to $781,435 for the nine months ended September 30, 2008, compared to $1.7 million for the same period in 2007. The higher total revenues for 2007 were primarily due to approximately $621,222 of research and development fees and licensing revenues from an agreement terminated in the first quarter of 2007.
Net income for the three months ended September 30, 2008, was $890,370 compared to a net loss of ($3.1) million for the same period in 2007. Net loss for the nine months ended September 30, 2008, decreased 55%, or $3.9 million to $3.2 million, compared with a net loss of $7.1 million for the same period in 2007. The decrease in the net loss was primarily due to the $4.0 million net gain from the termination of the lease on our corporate facility.
In May 2008, we entered into an agreement to terminate the lease of our
corporate facility for $4.1 million. Un
|SOURCE SCOLR Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved